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Summary
Background Several studies have shown that diabetes confers a higher relative risk of vascular mortality among 
women than among men, but whether this increased relative risk in women exists across age groups and within 
defined levels of other risk factors is uncertain. We aimed to determine whether differences in established risk factors, 
such as blood pressure, BMI, smoking, and cholesterol, explain the higher relative risks of vascular mortality among 
women than among men.
Methods In our meta-analysis, we obtained individual participant-level data from studies included in the Prospective 
Studies Collaboration and the Asia Pacific Cohort Studies Collaboration that had obtained baseline information on 
age, sex, diabetes, total cholesterol, blood pressure, tobacco use, height, and weight. Data on causes of death were 
obtained from medical death certificates. We used Cox regression models to assess the relevance of diabetes (any 
type) to occlusive vascular mortality (ischaemic heart disease, ischaemic stroke, or other atherosclerotic deaths) by 
age, sex, and other major vascular risk factors, and to assess whether the associations of blood pressure, total 
cholesterol, and body-mass index (BMI) to occlusive vascular mortality are modified by diabetes.
Findings Individual participant-level data were analysed from 980 793 adults. During 9·8 million person-years of 
follow-up, among participants aged between 35 and 89 years, 19 686 (25·6%) of 76 965 deaths were attributed to 
occlusive vascular disease. After controlling for major vascular risk factors, diabetes roughly doubled occlusive 
vascular mortality risk among men (death rate ratio [RR] 2·10, 95% CI 1·97–2·24) and tripled risk among women 
(3·00, 2·71–3·33; χ² test for heterogeneity p<0·0001). For both sexes combined, the occlusive vascular death RRs 
were higher in younger individuals (aged 35–59 years: 2·60, 2·30–2·94) than in older individuals (aged 70–89 years: 
2·01, 1·85–2·19; p=0·0001 for trend across age groups), and, across age groups, the death RRs were higher among 
women than among men. Therefore, women aged 35–59 years had the highest death RR across all age and sex groups 
(5·55, 4·15–7·44). However, since underlying confounder-adjusted occlusive vascular mortality rates at any age were 
higher in men than in women, the adjusted absolute excess occlusive vascular mortality associated with diabetes was 
similar for men and women. At ages 35–59 years, the excess absolute risk was 0·05% (95% CI 0·03–0·07) per year in 
women compared with 0·08% (0·05–0·10) per year in men; the corresponding excess at ages 70–89 years was 
1·08% (0·84–1·32) per year in women and 0·91% (0·77–1·05) per year in men. Total cholesterol, blood pressure, and 
BMI each showed continuous log-linear associations with occlusive vascular mortality that were similar among 
individuals with and without diabetes across both sexes.
Interpretation Independent of other major vascular risk factors, diabetes substantially increased vascular risk in both 
men and women. Lifestyle changes to reduce smoking and obesity and use of cost-effective drugs that target major 
vascular risks (eg, statins and antihypertensive drugs) are important in both men and women with diabetes, but 
might not reduce the relative excess risk of occlusive vascular disease in women with diabetes, which remains 
unexplained.
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Introduction
Worldwide, the age-standardised prevalence of diabetes 
more than doubled between 1980 and 2014, with the 
greatest relative and absolute increases seen in 
low-income and middle-income countries.1 Results from 
a previous large-scale collaborative meta-analysis of 
prospective studies done mostly in high-income 
countries showed that diabetes was associated with an 
approximate doubling in all-cause mortality risk, with 
the greatest excess due to deaths from occlusive vascular 
diseases (eg, ischaemic heart disease and ischaemic 
stroke).2,3 In those studies, the proportional increase in 
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See Online for appendix
occlusive vascular risk associated with diabetes was 
higher among women than among men.3 Similarly, 
findings from a large Chinese study showed somewhat 
larger relative risks associated with diabetes for vascular 
mortality in women than in men.4 However, adjustment 
for other established vascular risk factors (eg, blood 
pressure and cholesterol) was not always possible in 
these studies, so the larger relative risks seen in women 
could be due to differences in the extent of confounding 
by these factors. By contrast, in a large study of Mexican 
adults,5 diabetes conferred a much larger overall 
proportional increase in mortality risk than had been 
seen in these previous studies, and this relative risk was 
identical in men and women.
We aimed to assess whether differences in established 
risk factors explain higher relative risks of vascular 
mortality among women than among men. We used 
individual participant data from adults included in the 
Prospective Studies Collaboration and the Asia Pacific 
Cohort Studies Collaboration to estimate sex-specific 
associations between diabetes and risk of occlusive 
vascular mortality in subgroups divided by age and other 
vascular risk factors. We also examined whether the 
relevance of blood pressure, blood cholesterol, and body-
mass index (BMI)—factors that might cause or be caused 
by diabetes—to occlusive vascular mortality risk varied 
with the presence or absence of diabetes.
Methods
Study population and procedures
This meta-analysis comprises individual participant data 
collected from prospective observational studies included 
in the Prospective Studies Collaboration and Asia Pacific 
Cohort Studies Collaboration (appendix).6,7 Baseline data 
collection ranged from 1949 to 1997 and last follow-up from 
1985 to 2002. Details of study selection, data collection, and 
statistical methods used have been described previously.6,7 
Participants were included in our analyses if they had 
mortality follow-up data in the age range 35–89 years and 
had data on diabetes status, sex, tobacco use (self-reported), 
blood pressure, total cholesterol, height, and weight 
(measured in 66 cohorts but self-reported in two studies8,9 
of US health professionals; appendix).
Diabetes was defined if any of the following criteria were 
met: self-reported doctor diagnosis, measured fasting 
plasma glucose concentration of 7 mmol/L or higher 
(or ≥11·1 mmol/L if postprandial), or fasting serum glucose 
concentration of 6·1 mmol/L or higher (or ≥10 mmol/L if 
postprandial). We were not able to differentiate between 
diabetes types. BMI was calculated as the weight in kg 
divided by the square of the height in m (kg/m²). HDL 
cholesterol concentration was available in a subset of 
participants. Analyses were restricted to participants with 
no self-reported history of ischaemic heart disease or stroke, 
and with complete information on baseline covariates.
Research in context
Evidence before this study
Several large prospective studies and meta-analyses of such 
studies—especially the extensive collaborative meta-analysis 
by the Emerging Risk Factors Collaboration—have shown 
that individuals with diabetes are predisposed to increased 
vascular mortality, particularly from occlusive causes, and a 
higher relative risk exists among women than among men. 
Despite these studies, reasons for these sex differences are still 
unclear; however, they might relate to differential confounding 
by other established major vascular risk factors, such as blood 
pressure, total cholesterol, body-mass index (BMI), and 
smoking status. 
Added value of this study
Using individual participant-level data from nearly 1 million 
adults from the Prospective Studies Collaboration and Asia 
Pacific Cohort Studies Collaboration with complete 
measurement of established major vascular risk factors, we 
assessed sex-specific differences in the association between 
diabetes and occlusive vascular mortality across age groups 
and established major vascular risk factors. This meta-analysis 
adjusts for these major risk factors when analysing this 
association. Even after controlling for total cholesterol, blood 
pressure, BMI, and smoking status, diabetes conferred a 
doubling in occlusive vascular mortality risk among men aged 
35–89 years, but a tripling in risk among similarly aged  
women. Among women especially, diabetes death rate ratios 
were higher at younger ages than at older ages, so that at 
ages 35–59 years, diabetes was associated with a five to 
six times increased risk of occlusive vascular mortality. Total 
cholesterol, blood pressure, and BMI each had continuous 
log-linear associations with occlusive vascular mortality that 
were similar in strength among those with and those without 
diabetes irrespective of sex. Because those with diabetes were 
at a much higher risk than those without diabetes, however, 
the absolute relevance of these risk factors to vascular 
mortality risk was much greater among those with diabetes 
than those without.
Implications of the available evidence
Public health strategies aimed at lifestyle changes 
(particularly with respect to smoking and adiposity) and wider 
use of cost-effective drug treatments (eg, statin-based 
regimens and blood-pressure-lowering drugs) to reduce 
vascular risks are important among both men and women 
with diabetes. However, our results suggest that the larger 
death rate ratios associated with diabetes among women, 
compared with those among men, do not seem to be 
explained by these established major vascular risk factors. 
Future research should consider which emerging risk factors 
account for the relative excess risk of occlusive vascular 
disease among women with diabetes.
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Outcomes
Causes of death were determined from the reported 
underlying cause of death from medical death 
certificates, which is ascribed by use of an international 
convention.10 In most studies, the underlying cause of 
death was confirmed by a physician using medical 
records or autopsy findings. We mapped causes of death 
to the International Statistical Classification of Diseases 
and Related Health Problems, ninth revision (ICD-9) 
and categorised them as either vascular (codes 390–459, 
and 798)—from which occlusive vascular deaths were 
defined as death from ischaemic heart disease (410–414), 
ischaemic stroke (433–434), and other atherosclerotic 
deaths (440, 443, 445), and non-occlusive vascular deaths 
constituted all remaining vascular codes—or non-
vascular deaths, which were separated into cancer deaths 
(140–208) and other medical or external deaths (except 
deaths directly attributed to diabetes, including acute 
diabetic crises—ie, 250).
Data analysis
We estimated the sex-specific prevalence of diabetes 
separately by age and by levels of other vascular risk 
factors (eg, BMI, cholesterol, blood pressure). We used 
Cox regression stratified by study (which yields an 
approximately inverse-variance weighted average of the 
log death rate ratio [RR] from each study) to estimate the 
relevance of diabetes to cause-specific mortality, yielding 
death RRs over the average study period, adjusted for 
(or stratified by) age at risk (within 5-year age bands from 
35–39 to 85–89 years), sex, BMI, systolic and diastolic 
blood pressure, total cholesterol, and smoking status 
(classified into three categories: never smoked any type 
of tobacco regularly, current cigarette smoker, and former 
or other—including ex-smoker of any type of tobacco, 
current smoker of pipe or cigar, or smoking status not 
known). We assessed heterogeneity using Cochran’s 
Q statistic.
We then estimated the absolute occlusive vascular 
mortality rates in 12 groups defined by diabetes 
(yes or no), sex (male or female), and age group at risk 
(30–59, 60–69, or 70–89 years) using Poisson regression 
to standardise to the average levels of all confounders 
and to the information-weighted average absolute 
occlusive vascular mortality rates seen across the 
different studies. We then calculated the difference in 
these confounder-adjusted rates (between participants 
with and without diabetes) by age and sex, along with 
their 95% CIs. All rates are reported as percentage 
per year.
To determine whether the relevance of systolic blood 
pressure, total cholesterol, or BMI to occlusive vascular 
mortality risk differed between participants with and 
without diabetes, we divided participants into groups 
defined by diabetes status and then by levels of each risk 
factor (six groups). After adjustment for age, sex, study, 
smoking status, and the other two risk factors not being 
directly assessed, occlusive vascular death RRs were 
estimated for each group relative to the group with the 
lowest level of the risk factor in participants without 
diabetes (ie, the reference group). We plotted these death 
RRs against usual (ie, long-term average) systolic blood 
pressure and total cholesterol11,12 and against baseline 
BMI (since there was little evidence of regression to the 
mean for BMI in these data).13 95% CIs were calculated 
using the variance of the log risk, which ascribes an 
appropriate variance to the log of the death RR in every 
group (including the reference group).14 We did sensitivity 
analyses including participants excluded for previous 
cardiovascular disease, and also after excluding studies of 
only men or only women, and studies that contributed 
the most to between-study heterogeneity.
Analyses were done with SAS version 9.3 and 
R version 2.11.1.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Figure 1: Age-specific and sex-specific relevance of diabetes at study recruitment to occlusive vascular mortality
Analyses are stratified by study and adjusted for age at risk, BMI, systolic and diastolic blood pressure, total 
cholesterol, and smoking status. Each diamond is the inverse-variance weighted average of the two estimates for 
men and women. The size of the blocks reflects the amount of statistical information (ie, the inverse-variance of 
the log death RR). RR=rate ratio.
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Results
From 68 prospective studies in the Prospective Studies 
Collaboration and Asia Pacific Cohort Studies 
Collaboration studies database, individual participant-
level data for 1 017 259 participants were obtained, and 
980 793 adults (568 525 [58·0%] men vs 412 268 [42·0%] 
women) were eligible for analyses (8697 were excluded 
for a history of ischaemic heart disease or stroke and 
27 769 for having incomplete information on baseline 
covariates). The studies were done in 19 countries, and 
included 516 780 (52·6%) participants from western and 
central Europe, 271 290 (27·7%) from southeast 
Asia, 122 330 [12·5%] from North America, and 70 393 
(7·2%) from Australasia (appendix). Mean age at 
recruitment was 46 years (SD 10) for the analysed 
participants and mean age at occlusive vascular death in 
the 19 686 participants who died from these causes 
between ages 35 and 89 years was 66 years (SD 11).
Overall, 42 451 (4·3%) of 980 793 participants reported 
having diabetes at recruitment (28 450 [5·0%] of 
568 525 men, and 14 001 [3·4%] of 412 268 women; 
appendix). The prevalence of diabetes increased with age, 
from 2·1% in men and 1·4% in women at age 40 years, to 
8·9% in men and 6·0% in women by age 70 years 
(appendix). Of the 58 700 participants who reported no 
history of diabetes but who had a measurement of 
glucose, only 1174 (2·0%) had a glucose measurement 
that indicated they had undiagnosed diabetes and were 
counted as having diabetes in the main analyses.
The prevalence of diabetes increased with increasing 
BMI, systolic blood pressure (adjusted for BMI), and 
total cholesterol (adjusted for BMI), and decreased with 
increasing HDL cholesterol (HDL cholesterol was 
assessed in a subset of 168 341 participants). The 
prevalence of diabetes was broadly similar irrespective of 
smoking status (appendix).
Figure 2: Sex-specific relevance of diabetes at study recruitment to occlusive vascular mortality at ages 35–89 years, by baseline BMI (A), total cholesterol (B), systolic blood pressure (C), 
and smoking status (D)
Each risk factor was split into three strata; approximate thirds for the range of values for BMI, total cholesterol, and systolic blood pressure, and three categories for smoking status. Analyses are 
stratified by study and adjusted for age at risk, BMI, systolic and diastolic blood pressure, total cholesterol, and smoking status (apart from the analyses stratified by smoking status). Each diamond is 
the inverse-variance weighted average of the two estimates for men and women. The size of the block reflects the amount of statistical information (ie, the inverse-variance of the log death RR). 
RR=rate ratio. *Includes ex-smokers of any type of tobacco, current smokers of other types of tobacco, or smoking status not known. 
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During 9·8 million person-years of follow-up, in 
participants who were aged between 35 and 89 years, 
76 765 participants died, including 19 686 (25·6%) from 
occlusive vascular causes, of whom 17 919 (91·0%) died 
from ischaemic heart disease, 1499 (7·6%) from isch-
aemic stroke, and 268 (1·4%) from other atherosclerotic 
diseases. Figure 1 summarises the adjusted age-specific 
and sex-specific death RRs (participants with diabetes vs 
those without) for occlusive vascular mortality (stratified 
by study and adjusted for age at risk, BMI, systolic and 
diastolic blood pressure, total cholesterol, and smoking 
status). Overall, at ages 35–89 years, diabetes more than 
doubled occlusive vascular mortality risk (death RR 2·30, 
95% CI 2·18–2·44), but the death RR was higher for 
women (3·00, 2·71–3·33) than for men (2·10, 1·97–2·24). 
The death RRs were higher at younger ages than at older 
ages (figure 1; p=0·0001 for trend across age groups). 
This finding was especially apparent among women, for 
whom the diabetes death RR was 5·55 (95% CI 
4·15–7·44) at ages 35–59 years. These higher death RRs 
in women largely persisted within levels of other vascular 
risk factors (figure 2). When we did analyses separately 
for ischaemic heart disease and ischaemic stroke, the 
age-specific and sex-specific death RRs were similar to 
those seen for all occlusive vascular deaths considered 
together (p<0·05 for the heterogeneity test between men 
and women for overall death RRs for both ischaemic 
heart disease and ischaemic stroke; appendix); we did 
not analyse deaths from other specific atherosclerotic 
diseases because small numbers precluded reliable 
analyses. The results were not materially changed after 
excluding studies that recruited only men or only 
women (appendix), or when excluding the studies that 
contributed most to between-study heterogeneity 
(data not shown). Sex differences in death RRs were also 
evident among participants who reported a history of 
ischaemic heart disease or stroke (appendix) and 
separately within each of the three studied regions 
(ie, Europe, the USA or Australasia, and Asia; appendix).
The underlying confounder-adjusted occlusive vascular 
mortality rates at any given age were higher among men 
than women; therefore, the age-specific absolute excess 
occlusive vascular mortality risk associated with diabetes 
was similar for men and women (table). At ages 
35–59 years, the adjusted excess mortality associated 
with diabetes was 0·05% (95% CI 0·03–0·07) per year in 
women compared with 0·08% (0·05–0·10) per year in 
men; the corresponding excess mortality at ages 
70–89 years was 1·08% (0·84–1·32) per year in women 
and 0·91% (0·77–1·05) per year in men.
For usual (ie, long-term average level) total cholesterol, 
usual systolic blood pressure, and baseline BMI, log-linear 
positive associations with occlusive vascular mortality 
risk were seen both among participants with and without 
diabetes (figure 3). For total cholesterol and BMI, the 
strength of the associations was similar for participants 
with and those without diabetes, but for systolic blood 
pressure the association was somewhat weaker among 
those with diabetes than among those without diabetes. 
However, because the absolute risk of occlusive vascular 
mortality was appreciably higher in participants with 
diabetes, the crude absolute risks associated with higher 
levels of all three of these vascular risk factors were much 
greater among participants with diabetes than those 
without. These findings were similar when men and 
women were considered separately (appendix).
For non-occlusive vascular mortality, the death RRs 
comparing individuals with and without diabetes were 
somewhat weaker than for occlusive vascular mortality, 
but, as for occlusive vascular mortality, death RRs were 
larger for women than for men (figure 4). The death RRs 
for cancer mortality were considerably smaller (over-
 all death RR 1·17, 95% CI 1·10–1·23) than for vascular 
causes, and similar among men and women. Diabetes 
was associated with an approximate doubling in the 
risk of death from the composite of any other medical  or 
external cause (death RR 1·87, 1·78–1·97; excluding 
142 deaths attributed directly to diabetes).
Diabetes No diabetes Rate difference (95% CI)
Deaths (n) Person-years Adjusted rate* Deaths (n) Person-years Adjusted rate*
Aged 35–59 years
Men 252 151 321 0·13% 4579 4 168 660 0·06% 0·08% (0·05–0·10)
Women 60 72 756 0·06% 496 2 878 295 0·01% 0·05% (0·03–0·07)
Aged 60–69 years
Men 390 62 605 0·52% 5096 1 062 761 0·24% 0·28% (0·22–0·34)
Women 136 32 547 0·28% 974 720 144 0·07% 0·20% (0·13–0·27)
Aged 70–89 years
Men 460 30 489 2·05% 4473 350 754 1·14% 0·91% (0·77–1·05)
Women 252 13 001 1·92% 2518 267 099 0·84% 1·08% (0·84–1·32)
Data are n, person-years, or percentage per year, with 95% CIs in parentheses where stated. *Absolute rates are estimated by use of Poisson regression stratified by study and 
adjusted for age at risk (in 5-year age groups), BMI, systolic and diastolic blood pressure, total cholesterol, and smoking status.
Table: Adjusted rates of occlusive vascular death among people with and without diabetes at recruitment, by age and sex
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Discussion
In this analysis of individual participant-level data from 
nearly 1 million adults with no previous vascular disease 
who were followed up prospectively to monitor mortality, 
we determined that having diabetes at recruitment 
was associated with a doubling in death rates from 
ischaemic heart disease and ischaemic stroke among 
men, but a tripling of these death rates among women. 
For both men and women, the death RRs for occlusive 
vascular mortality were greater in early middle-aged 
(ie, 35–59 years) than in older patients, so that diabetes 
was associated with an almost six times higher occlusive 
vascular death rate among women aged 35–59 years, 
even after controlling for other established major 
vascular risk factors.
At any given age, the underlying confounder-adjusted 
occlusive vascular death rates were higher for men than 
for women, so despite higher death RRs among women 
than among men, we estimate that the absolute excess 
risk of occlusive vascular mortality associated with 
diabetes was similar in men and women. The adjusted 
occlusive vascular mortality rates among women with 
diabetes aged 35–59 or 60–69 years were similar to those 
among men without diabetes of a similar age (table).
Sex differences in the relative excess of occlusive 
vascular risk associated with diabetes have been 
reported in several studies,3,4,15,16 but most have not 
considered how this relative excess risk translates to 
absolute excess risk. By contrast with these studies, the 
main strength of our analysis is the inclusion of studies 
with complete availability of baseline information on 
systolic and diastolic blood pressure, total cholesterol, 
BMI, and smoking status in a large number of 
apparently healthy people (ie, without occlusive vascular 
disease) followed up prospectively. Underprescription 
of cardiovascular-risk-modifying therapy among women 
has been described,17 but since many of the cohort 
studies included in our meta-analysis were completed 
before the introduction of statin therapy and widespread 
screening for high blood pressure for primary 
prevention, our findings suggest that underprescription 
among women is unlikely to account for the differences 
between the sexes in our calculated diabetes death RRs. 
Indeed, our findings remain relevant, since results from 
a study of 1·9 million patients in an English primary-
care database who were identified and followed up 
between 1998 and 2010 showed that relative risks for 
non-fatal ischaemic heart disease were somewhat 
higher among women than among men, even after 
adjustment for disease management via antihypertensive 
medication and statin use16 (which are similarly 
efficacious in both sexes18,19). However, sex differences in 
the management of cardiac disease during and after 
treatment in hospital might, to some extent, help to 
account for the higher diabetes death RRs among 
women than among men.20
Figure 3: Relevance of total cholesterol (A), systolic blood pressure (B), and BMI (C) to RR of occlusive vascular mortality at ages 35–89 years, by diabetes 
status at study recruitment
Analyses are stratified by study and sex, and adjusted for age at risk, smoking status, and, if appropriate, total cholesterol, systolic and diastolic blood pressure, and 
BMI. Usual total cholesterol and systolic blood pressure are the long-term average level of that risk factor. Regression dilution ratios of 0·65 for total cholesterol and 
0·67 for systolic blood pressure were calculated by regressing serial measurements from 175 000 participants with at least one re-measurement, on average, 3 years 
later, on baseline levels of these risk factors. No such adjustment was applied for BMI, since one single measurement at baseline was highly correlated with long-term 
BMI.  The vertical lines through the plotted boxes are 95% CIs that reflect only the variance of the log risk in that group (and are therefore shown for every group 
including the reference group), and the size of each box reflects the amount of statistical information. RR=rate ratio.
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Several hypotheses that could account for sex 
differences in diabetes-associated vascular risk remain 
unexplored. Hormone-replacement therapy has been 
shown to increase cardiovascular risk,21 and both 
oestrogens and androgens can affect lipid metabolism;22 
therefore, future analyses considering sex-hormone 
concentrations and subclasses of lipids would be of 
interest. 23–25 Sex differences in inflammation might also 
exist,26 and since targeting interleukin-1β can reduce 
occlusive vascular risk,27 inflammation should be a focus 
of future research aimed at devising novel therapeutic 
approaches.
The main limitation of this study was the absence 
of phenotypic information on diabetes and its 
complications, which have been shown to affect risk 
(eg, type of diabetes, glycaemic control,3 duration of 
diabetes,28 and the presence of complications such as 
renal disease29). Other studies have considered these 
factors, but rarely are all factors comprehensively 
measured, and whether sex differences in diabetes 
phenotype could account for sex differences in the 
relation of diabetes with occlusive vascular mortality 
risk is unclear. For example, type 1 diabetes might be 
associated with high cardiovascular risk,30 but among 
adults with diabetes the proportion who have 
type 1 diabetes is usually low in most populations 
(3–15%) and, if anything, this proportion is higher in 
men than in women.31 Differences in glycaemic control 
are also not a clear explanation for sex differences 
observed in the English primary care study of 1·9 million 
patients,16 since diabetes was associated with a somewhat 
higher risk of ischaemic heart disease in women than in 
men despite similar prescription of diabetes treatments, 
and glycaemic control being, if anything, slightly better 
in women than in men.16 However, in a prospective 
study of 150 000 Hispanic adults from Mexico City, 
Mexico,5 no difference was seen between men and 
women in the diabetes death RR for vascular causes 
(or for all causes combined). Notably, both men and 
women in that study had a similar duration of diabetes 
and similarly poor glycaemic control. Additionally, our 
meta-analysis does not take into account the effects of 
undiagnosed diabetes at baseline or the development of 
new diabetes during follow-up. However, among 
participants with glucose measurements, only 2% of 
those not reporting a diagnosis at baseline had measure-
ments that indicated the presence of undiagnosed 
diabetes, and, therefore, if a similarly small percentage 
of participants developed diabetes during follow-up 
then the reported death RRs would not be greatly 
affected since these people would contribute only a very 
small proportion of those classified as not having 
diabetes at baseline. Another limitation of this study is 
that the cohorts were recruited some years ago, with 
baseline data ranging from 1949 to 1997. Although this 
aspect of the study also has some advantages (primarily 
that the participants were recruited before widespread 
treatment with statins or blood-pressure-lowering 
medication), we must recognise that treatment of both 
diabetes and vascular risk factors have changed 
substantially over the past few decades and these 
changes might affect the current vascular risks 
associated with a diagnosis of diabetes. Hence, analysis 
of recently established and future prospective cohorts is 
needed to assess whether developments in the treatment 
of both diabetes and vascular risk factors over the past 
few decades are having any effect on contemporary 
diabetes-associated risks and on the age and sex 
differences in these associations.
Our analyses showed that the strength of the 
association of total cholesterol and BMI with occlusive 
vascular mortality risk was similar irrespective of the 
presence of diabetes, and that at any level of these 
risk factors, diabetes carries a substantially increased risk 
(figure 3). Hence, the absolute relevance of these risk 
factors to occlusive vascular disease would be greater for 
people with diabetes than those without. Although the 
association between systolic blood pressure and occlusive 
vascular mortality risk was slightly weaker among 
participants with diabetes, the absolute relevance to risk 
would again be greater among those with diabetes than 
those without diabetes.
Figure 4: Sex-specific relevance of diabetes at study recruitment to cause-specific and all-cause mortality at 
ages 35–89 years
Analyses are stratified by study and adjusted for age at risk, BMI, systolic and diastolic blood pressure, total cholesterol, 
and smoking status. Each diamond is the inverse-variance weighted average of the two estimates for men and women. 
The size of the block reflects the amount of statistical information (ie, the inverse-variance of the log death RR). RR=rate 
ratio. *Except for deaths attributed directly to diabetes, including acute diabetic crises (ICD-9 code 250), which occurred 
among 107 of the participants with diabetes at recruitment and 35 of the participants without diabetes at recruitment.
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In the WHO 2013–20 non-communicable disease global 
plan targets,32 one of the main priorities is a 25% reduction 
in the risk of premature mortality from cardiovascular 
diseases and diabetes by 2025 relative to 2013. The 
continuous nature of the associations of conventional risk 
factors with vascular events among people with diabetes 
in our analyses supports data from randomised trials33,34 
that suggest that the vascular benefits of intensive 
versus recommended standard blood-pressure-lowering 
medications and targets are similar among those with and 
without diabetes, and support the existing guideline 
recommendation35 favouring treatment of absolute risk 
of disease rather than threshold concentrations of 
cholesterol. Since the relevance of blood pressure, blood 
cholesterol, and BMI to occlusive vascular mortality risk 
was broadly similar among people with and without 
diabetes, the absolute benefits of strategies to achieve 
effective lowering of these multiple risk factors in both 
women and men with diabetes will help to achieve global 
health priorities. However, the use of only these strategies 
would not be expected to reduce all the relative excess of 
diabetes-associated vascular risk seen among women, 
since this excess risk does not seem to be explained by 
these traditional major vascular risk factors.
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